Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Santarus, Inc. recently filed a patent infringement lawsuit against Mylan, Inc. (MYL - Analyst Report) which is looking to launch a generic version of Santarus’ Fenoglide (fenofibrate - 40 mg and 120 mg) tablets. The two listed patents are scheduled to expire in 2024.

Santarus has an exclusive license agreement with Cowen Healthcare Royalty Partners and Shore Therapeutics, Inc. for the commercialization of Fenoglide in the US. Fenoglide is indicated to treat adults with hyperlipidemia, mixed dyslipidemia and hypertriglyceridemia.

Fenoglide revenues for the nine months ending Sep 30, 2012 were $5.6 million.

Our Take

The filing of the patent infringement lawsuit within 45 days from the date of receipt of notice from Mylan is in line with our expectations. This will ensure that the FDA cannot grant final approval to Mylan’s generic for up to 30 months or the court’s decision, whichever is earlier.

We note that another generic company, Impax Laboratories (IPXL) had also challenged the Fenoglide patent. However, Shore Therapeutics had signed a settlement agreement with Impax regarding the patent infringement litigation. Under the terms of the agreement, Impax was granted a sub-license under which it can start selling its generic version of Fenoglide on Oct 1, 2015 or earlier under some circumstances.   

With Fenoglide not being a major contributor to the top-line, we do not expect the news regarding the patent infringement lawsuit to have a major impact on Santarus’ shares.

In fact, we expect investor focus to remain on the commercialization of Uceris and the Zegerid re-launch. Earlier this month, Santarus had gained FDA approval for Uceris for remission in patients suffering from mild-to-moderate ulcerative colitis. Uceris is likely to be launched in Mar 2013.

Santarus carries a Zacks Rank #4 (Sell) while Mylan carries a Zacks Rank #2 (Buy). Right now, Furiex Pharmaceuticals, Inc. (FURX - Snapshot Report) and Valeant Pharmaceuticals International, Inc. (VRX - Snapshot Report),  look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%